A company submitted study data supporting a PMA submission to the FDA.
3 reports, 2 independent
Updated Jun 30
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company submitted study data supporting a PMA submission to the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Granules India Limited is submitting ANDA and Paragraph IV certification to the FDA.Sub-event
Study data supported PMA submission to the FDA.1 source
Keep exploring
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- A company is seeking definitive data for a pre-NDA meeting with the FDA in Raleigh.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- GlobeNewswireNyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium
- Unknown outlet